Slide 1: Financial Statements Release 2024
Financial Statements Release 2024 4 March 2025
Slide 2: Disclaimer
Disclaimer The following applies to this presentation, the oral presentation of the information in this presentation by Oriola Corporation (the “Company” or “Oriola”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the “In
Slide 3: Agenda
Agenda 1 FY 2024 highlights 2 Operating environment 3 Segments 4 Financial review Q&A Q4 2024 4 MARCH 2025 3
Slide 4: Strategy implementation enhances financial performance
Strategy implementation enhances financial performance • Sales growth and improved profitability supported by both segments. • Good progress with refined strategy – strengthened customer- FY 24 Net sales centricity, expanded wholesale business and introduced data-driven 1.7 (1.5) +12% services. EUR
Slide 5: Board's dividend proposal
Board’s dividend proposal Dividend payout EUR per share EPS DPS The Board of Directors proposes to the AGM that a 0.07 0.07 dividend of EUR 0.07 per share be paid for 2024. 0.06 0.06 0.06 Record date: 4 April 2025 0.04 0.03 Payment date: 15 April 2025 -0.01 Dividend policy Oriola aims to pay out an
Slide 6: Operating environment
Operating environment • Overall operating environment has stabilised, consumer confidence was weak in Finland and in Sweden. • Cost inflation has slowed down, with more normalised energy and fuel prices. • The challenges in the availability of pharmaceuticals continues in Europe. • Value of the phar
Slide 7: Q4: Distribution segment
Q4: Distribution segment • Net sales grew 16% to EUR 362 • Stable market shares in Finland, (312) million – customer shifting to decline in Sweden. Oriola’s inventory in Q3. • In 2024, a strategic focus area within • Organic growth 2% – market distribution was to enhance customer- volumes grew, sign
Slide 8: Q4: Wholesale segment
Q4: Wholesale segment • Net sales grew 5% to EUR 79 (75) • Long-term strategic goal to grow million. wholesale business. • Growth in Finland was supported by • In 2024, developed capabilities and wider offering and new sales expanded offering. channels, and in Sweden by Oriola’s • A strong Q4 with d
Slide 9: Sale of Svensk dos AB
Sale of Svensk dos AB • The agreement to sell all shares in Svensk dos AB to Apotekstjänst Sverige AB was signed in October 2023. • On 29 April, the Swedish Competition Authority (Konkurrensverket) announced its decision on prohibiting Oriola’s sale of Svensk dos AB to Apotekstjänst Sverige AB due t
Slide 10: Financial review
Financial review Q4 2024 4 MARCH 2025 10
Slide 11: Q4: Adjusted EBIT up by 19%
Q4: Adjusted EBIT up by 19% Net sales by segment EUR million Adjusted EBIT* by segment EUR million +14% +14% +5% +19% +16% 440.7 436.8 6.4 4.0 6.2 0.2 -0.2 6.1 5.4 1.0 50.2 384.1 386.6 Q4 23 excl. Q4 23 incl. Distribution Wholesale Q4 24 incl. Q4 24 excl. Q4 23 Q4 23 incl. Distribution Wholesale Gro
Slide 12: Solid development on topline
Solid development on topline Invoicing EUR million Net sales EUR million Adjusted EBIT* EUR million +5% +12% +30% 3 588 3 772 +14% 1 494 1 680 +2% +19% 21.7 16.7 963 983 387 441 5.4 6.4 Q4 23 Q4 24 YTD 23 YTD 24 Q4 23 Q4 24 YTD 23 YTD 24 Q4 23 Q4 24 YTD 23 YTD 24 • Customer changing from consignment
Slide 13: Distribution segment
Distribution segment Net sales EUR million Adjusted EBIT EUR million Share of net sales1 % +15% +31% 81% 1 365 +16% 1 189 +22% 19.0 14.5 312 362 4.8 5.9 Q4 23 Q4 24 YTD 23 YTD 24 Q4 23 Q4 24 YTD 23 YTD 24 • Growth due to a customer changing to • Organic sales growth and lower freight costs Share of
Slide 14: Wholesale segment
Wholesale segment Net sales EUR million Adjusted EBIT EUR million Share of net sales1 % +3% +6% 19% 306 316 8.9 9.5 +5% +10% 75 79 1.8 2.0 Q4 23 Q4 24 YTD 23 YTD 24 Q4 23 Q4 24 YTD 23 YTD 24 • Growth in Finland supported by the wider • Profitability in Finnish wholesale slightly Share of adj. EBIT2
Slide 15: Profit at last year's level
Profit at last year’s level Net profit EUR million 1-12 2024 27.2 -13.6 • EBITDA below last year due to adjusting items 13.6 2024 of EUR -8.1 (-0.4) million. -7.3 1-12 • Impairment write-downs related to ERP of EUR -24.8 1.9 million in Q3 2024 and dose business EUR 21.4 million in Q3 2023. -1.5 • To
Slide 16: Positive operative cash flow
Positive operative cash flow Changes in cash position per item EUR million 1-12 2024 -7.6 21.4 -2.9 -2.8 • Net cash flow from operating -27.9 activities in Jan–Dec 2024 2024 27.2 138.4 EUR 38.7 (9.6) million. 1-12 -17.0 -3.1 • Positive impact from change -12.7 113.5 0.4 in NWC by EUR 21.4 (-13.2) mi
Slide 17: Net debt on a low level
Net debt on a low level Net interest-bearing debt EUR million Net interest-bearing debt items 19 31 Dec 31 Dec Abs. EUR million 2024 2023 change 9 -16.7 Bank loans (syndicated bank & term) 31.0 59.1 -28.1 -2 Commercial papers 24.8 39.3 -14.5 -7 -9 Advance payment from pharmacies 7.9 10.4 -2.4 -12 -2
Slide 18: Solid financial position
Solid financial position Gearing1 and equity ratio % 1-12 2024 Gearing Equity ratio 23 21 • The negative result and 19 19 18 impairment from 17 17 15 Kronans Apotek had a 9 negative impact on the 5 net result and the Equity ratio. -1 -6 -5 -8 -12 -28 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 1
Slide 19: Kronans Apotek (Swedish Pharmacy Holding)
Kronans Apotek (Swedish Pharmacy Holding) 2024 2023 Change 2024 2023 Change Key figures EUR million 10-12 10-12 % 1-12 1-12 % Net sales 288.2 283.5 1.7 1,151.1 1,126.9 2.1 EBITA -4.6 -6.5 29.3 -5.9 0.7 EBITA % -1.6 -2.3 -0.5 0.1 Adjusted EBIT -5.1 -5.1 -1.2 -8.0 -2.0 Adjusted EBIT % -1.8 -1.8 -0.7 -
Slide 20: Outlook
Outlook In 2025, the pharmaceutical distribution market is expected to continue to grow. Value growth is expected to be driven by high-value pharmaceuticals and products requiring advanced logistics. The uncertainty in the geopolitical environment remains, and the availability issues of certain phar
Slide 21: FY 24 Key takeaways
FY 24 Key takeaways Good financial performance with sales growth and improved profitability Strategy execution according to set strategic New operating model to enhance customer goals focus and drive growth
Slide 22: Our next events
Our next events week 11 Annual Report 2024 2 April 2025 Annual General Meeting 29 April 2025 Q1 2025 Interim Report Thank you for joining us!
Slide 23: Health for life